In this large multi‐center study, we analyzed the impact of PTEN deletions on tumor aggressiveness, patient prognosis, and p53 and p16 alterations, especially in muscle‐invasive urothelial bladder carcinomas to expand the results from our previous study on 686 pTa to pT4 urothelial bladder carcinomas. This evidence concerns the gene TP53 and neoplasm.